{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-157911","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.070532+00:00","generated_at":"2026-06-01T05:21:10.466309+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Pyxis Oncology appoints Michael A. Metzger (CEO of Syndax) to board effective June 10, 2024","bullets":["Michael A. Metzger appointed to Pyxis Oncology Board as Class II director, effective June 10, 2024.","Metzger is CEO of Syndax Pharmaceuticals (Nasdaq: SNDX) and has over 25 years biopharma experience.","He will serve on Audit and Compensation Committees; received stock options for 70,683 shares vesting over three years.","Board determined Metzger qualifies as independent director under Nasdaq standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-157911","json":"https://secwatch.observer/filing/0001193125-24-157911.json","markdown":"https://secwatch.observer/filing/0001193125-24-157911.md","text":"https://secwatch.observer/filing/0001193125-24-157911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/0001193125-24-157911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/d843596d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:21:10.466309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87f1e2adea","claim":"Michael A. Metzger was appointed as Director at Pyxis Oncology, Inc..","evidence_excerpt":"On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/0001193125-24-157911-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}